Aomingcheng (Shenzhen) Biotechnology Co.

, Ltd. focuses on developing a proprietary "Data-Large Model-Agent" ecosystem to revolutionize life sciences through advanced AI-driven research and clinical applications., Ltd. The company provides a comprehensive matrix of intelligent agents and diagnostic solutions, such as the OS-TuFEst® multi-cancer screening platform, which leverages cfDNA fragmentomics and AI models to deliver high-sensitivity early disease detection, drug R&D support, and personalized health management. The company generates revenue by providing clinical diagnostic services to hospitals and physical examination centers, collaborating with pharmaceutical companies on drug discovery, and licensing its AI4S platform capabilities. In the future, the company will focus on breakthroughs in three areas: First, enabling AI to move from "representation learning" to "mechanism modeling", not just predicting results, but approximating the intrinsic logic of disease development; second, equipping AI with "problem-defining capabilities", enabling it not only to answer questions but also to identify key variables in complex systems, assisting in formulating more valuable scientific questions; and third, developing AI's "exploratory reasoning capabilities", supporting an integrated research process from hypothesis generation to path deduction. In the long term, this system is expected to extend into "medical AGI" covering the entire life process.

1. Series A

   Apr 24, 2026

   Amount

   $15M

   Investors

   Locked